What is claimed is:

1. Use of a pharmaceutical composition in the manufacture of a medicament for reducing risk of a cardiovascular event in a subject with at least one risk factor for cardiovascular disease who is at LDL-C goal, the use comprising that the pharmaceutical composition comprising about 4 g of icosapent ethyl is to be administered to the subject per day for a period effective to reduce risk of the cardiovascular event in the subject.

2. The use of claim 1, wherein the cardiovascular event is one or more of: cardiovascular death, myocardial infarction, stroke, coronary revascularization, and unstable angina.

3. The use of claim 1, wherein the administration affects a relative risk reduction of said cardiovascular event of at least about 25%.

4. The use of claim 1, wherein the subject has a fasting baseline triglyceride level of 135 mg/dL to 500 mg/dL.

5. The use of claim 1, wherein the LDL-C goal is an LDL-C level of 40 mg/dL to 100 mg/dL.

6. The use of claim 1, wherein the subject has established cardiovascular disease.

7. The use of claim 1, wherein the subject has diabetes.

8. The use of claim 1, wherein the at least one risk factor for cardiovascular disease is selected from the following risk factors: (a) the subject is a male of at least 55 years of age or a female of at least 65 years of age, (b) the subject smokes cigarettes or has stopped smoking cigarettes within three months before administration of the pharmaceutical composition, (c) the subject has a blood pressure of at least 140 mmHg systolic or at least 90 mmHg diastolic, (d) the subject is receiving antihypertension medication, (e) the subject is a male with HDL-cholesterol level 40 mg/dL or less or is a female with HDL-cholesterol level 50 mg/dL or less, (f) the subject has a hs-CRP level of greater than 3 mg/L, (g) the subject has a creatine clearance between 30 mL/min and

60 mL/min, (h) the subject has non-proliferative retinopathy, (i) the subject has pre-proliferative retinopathy, (j) the subject has proliferative retinopathy, (k) the subject has maculopathy, (l) the subject has advanced diabetic eye disease or a history of photocoagulation, (m) the subject has micro- or macro-albuminuria, and (n) the subject has a asymptomatic ankle-brachial index of less than 0.9

9. The use of claim 1 wherein the pharmaceutical composition is to be administered to the subject in 1 to 8 dosage units per day.

10. The use of claim 1, wherein the icosapent ethyl comprises at least about 90 wt. % of all omega-3 fatty acids in the pharmaceutical composition.

11. The use of claim 1 wherein the icosapent ethyl comprises at least about 96 wt.% of all omega-3 fatty acids in the pharmaceutical composition.

12. The use of claim 1 further comprising a step of measuring the subject's baseline lipid profile prior to administering the pharmaceutical composition to the subject.

13. The use of claim 12, wherein the subject has one or more of: a baseline non-HDL-C value of 200 mg/dL to 300 mg/dL; a baseline total cholesterol value of 250 mg/dL to 300 mg/dL; a baseline VLDL-C value of 140 mg/dL to 200 mg/dL; a baseline HDL-C value of 10 to 30 mg/dL; and/or a baseline LDL-C value of 40 to 100 mg/dL.

14. The use of claim 1, wherein the subject: (a) has not been administered 200 mg or more per day of niacin and/or fibrates for at least 28 days before administration of the pharmaceutical composition; (b) has not been administered omega-3 fatty acid prescription for a period of time beginning 28 days prior to administration of the pharmaceutical composition; (c) has not ingested dietary supplements comprising omega-3 fatty acids for a period of time beginning 28 days prior to administration of the pharmaceutical composition.

15. The use of claim 1, wherein said period ends about 6 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or more than about 5 years after the first administration of the pharmaceutical composition.

16. The use of claim 1, wherein the subject is to be administered about 4 g of the pharmaceutical composition per day for at least about 3 years.

17. Use of icosapent ethyl in the manufacture of a medicament for delaying or preventing a major adverse cardiovascular event in a subject, the use comprising that about 4 g of icosapent ethyl is to be administered to the subject per day for a period effective to delay or prevent the major adverse cardiovascular event, wherein the subject is 50 years of age or older, has diabetes and at least one additional risk factor for cardiovascular disease.

18. The use of claim 17, wherein the at least one additional risk factor is selected from hypertension, smoking, retinopathy, and albuminuria.

19. The use of claim 17, wherein the subject has at least two additional risk factors for cardiovascular disease.

20. The use of claim 17, wherein subject has a baseline triglyceride level of at least 200 mg/dL.

21. The use of claim 17, wherein the major adverse cardiovascular event is selected from the group consisting of stroke, myocardial infarction, coronary revascularization, unstable angina, and cardiovascular death.

22. The use of claim 17, wherein the subject is on a statin therapy.

23. The use of claim 22, wherein the statin therapy is a stable statin therapy.

24. The use of claim 17, wherein the icosapent ethyl is present in a pharmaceutical composition and the icosapent ethyl comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition.

25. The use of claim 24, wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules.